BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has partnered with Mrs. Amy Ansfield Scott in order to assist with nationwide KOL engagement ahead of the commercial launch of PURE EP(tm) System in the U.S.
Mrs. Scott brings to the Company over 30 years of experience in medical devices, including over 20 years in electrophysiology (EP). Most recently, she served as Director of Strategic Partnerships for Biosense Webster (Johnson & Johnson), a role which she was responsible for primarily U.S. engagement of physicians and management of the company’s Scientific Advisory Board. Prior to that role, Mrs. Scott was managing a team responsible for driving customer engagement and education, including development of product demonstration and training sites, management of key accounts and liaison between internal clinical and field clinical trials teams. During her career with Biosense Webster, Mrs. Scott also served as Global Product Director for Atrial Fibrillation, the role in which she developed, executed and managed EP/Afib Centers of Excellence. She brings to BioSig extensive experience in defining customer needs and promoting key account relations and activities.
“An experienced and passionate leader like Amy is an invaluable addition to our team. Her expertise in building successful physician relationships and the depth of her marketing knowledge can significantly benefit our effort to launch and expand our clinical operations following our 510(k) clearance,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.
The Company announced that it received the 510(k) clearance for its PURE EP System on August 14, 2018. Earlier in the month, on August 1, 2018, the Company announced its intentions to list on the Nasdaq stock exchange.
“I’m delighted to join the BioSig team as the Company starts a new chapter. I have been impressed with the strong value proposition of PURE EP and the long-term vision of the management team. I look forward to helping the Company make its first steps in the clinical field,” commented Mrs. Scott.